Skip to main content
Erschienen in: Osteoporosis International 8/2016

14.04.2016 | Case Report

Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report

verfasst von: A. Karahasanovic, A.-L. Thorsteinsson, N. H. Bjarnason, P. Eiken

Erschienen in: Osteoporosis International | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Cystic fibrosis (CF) is a serious autosomal recessive genetic disorder associated with chronic lung disease, malabsorption, malnutrition, pancreatic insufficiency and premature respiratory failure. Recent advances in medical science and technology have increased the lifespan of patients with CF, albeit with long-term consequences of the disease, such as osteoporosis, becoming of increasing significance. The medical treatment of osteoporosis in patients with CF or after organ transplantation is still being explored, and no clear guidelines regarding the best choice of bisphosphonate exist. We report a case of a young woman with CF, lung transplantation and low bone mass developing long-term leukopenia after treatment with zoledronic acid. The leukopenia, with a strong affection of the neutrocytes, lasted for 4 months and the condition only went into remission after granulocyte-colony stimulating factor (G-CSF) treatment. It is important to be aware of symptomatic leukopenia in immunosuppressive patients after treatment with zoledronic acid.
Literatur
1.
Zurück zum Zitat Cystic Fibrosis Foundation (2013) Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report Cystic Fibrosis Foundation (2013) Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report
2.
Zurück zum Zitat Conwell LS, Chang AB (2014) Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 3:CD002010PubMed Conwell LS, Chang AB (2014) Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 3:CD002010PubMed
3.
4.
Zurück zum Zitat Stalvey MS, Clines GA (2013) Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes 20:547–552CrossRefPubMedPubMedCentral Stalvey MS, Clines GA (2013) Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes 20:547–552CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, Ontjes DA (1998) Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 128:186–193CrossRefPubMed Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, Lester GE, Ontjes DA (1998) Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 128:186–193CrossRefPubMed
6.
Zurück zum Zitat Chapman I, Greville H, Ebeling PR, King SJ, Kotsimbos T, Nugent P, Player R, Topliss DJ, Warner J, Wilson JW (2009) Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin Endocrinol (Oxf) 70:838–846CrossRef Chapman I, Greville H, Ebeling PR, King SJ, Kotsimbos T, Nugent P, Player R, Topliss DJ, Warner J, Wilson JW (2009) Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin Endocrinol (Oxf) 70:838–846CrossRef
7.
Zurück zum Zitat Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254CrossRefPubMed Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254CrossRefPubMed
8.
Zurück zum Zitat Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30:934–944CrossRefPubMed Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30:934–944CrossRefPubMed
9.
Zurück zum Zitat Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263CrossRefPubMed Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263CrossRefPubMed
10.
Zurück zum Zitat Aris RM, Lester GE, Renner JB, Winders A, Denene BA, Lark RK, Ontjes DA (2000) Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 162:941–946CrossRefPubMed Aris RM, Lester GE, Renner JB, Winders A, Denene BA, Lark RK, Ontjes DA (2000) Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 162:941–946CrossRefPubMed
11.
Zurück zum Zitat Derry CJ, Derry S, Moore RA (2012) Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2:CD008615PubMedPubMedCentral Derry CJ, Derry S, Moore RA (2012) Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2:CD008615PubMedPubMedCentral
12.
Zurück zum Zitat Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, Rockenschaub S, Berlakovich G, Steininger R, Klaushofer K, Oberbauer R, Muhlbacher F (2007) Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 7:1763–1769CrossRefPubMed Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, Rockenschaub S, Berlakovich G, Steininger R, Klaushofer K, Oberbauer R, Muhlbacher F (2007) Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 7:1763–1769CrossRefPubMed
13.
Zurück zum Zitat Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW (2006) Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239–248CrossRefPubMed Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW (2006) Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239–248CrossRefPubMed
14.
Zurück zum Zitat Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R (2003) Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63:1130–1136CrossRefPubMed Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, Steininger R, Grampp S, Klaushofer K, Delling G, Oberbauer R (2003) Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63:1130–1136CrossRefPubMed
15.
Zurück zum Zitat Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R (2004) Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 65:304–309CrossRefPubMed Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R (2004) Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 65:304–309CrossRefPubMed
16.
Zurück zum Zitat Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D (2012) Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab 97:4481–4490CrossRefPubMedPubMedCentral Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D (2012) Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab 97:4481–4490CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Jayakar BA, Abelson AG, Yao Q (2011) Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. Semin Arthritis Rheum 41:291–296CrossRefPubMed Jayakar BA, Abelson AG, Yao Q (2011) Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. Semin Arthritis Rheum 41:291–296CrossRefPubMed
18.
Zurück zum Zitat Reginster JY, Gritten C, Diverse P, Hauwaert PC, Crielaard JM, Halleux R, Franchimont P (1985) Treatment of Paget’s disease with low dose sodium etidronate (5mg/kg/day). Occurrence of reversible transient suspected leukopenia. Rev Rhum Mal Osteoartic 52:145–150PubMed Reginster JY, Gritten C, Diverse P, Hauwaert PC, Crielaard JM, Halleux R, Franchimont P (1985) Treatment of Paget’s disease with low dose sodium etidronate (5mg/kg/day). Occurrence of reversible transient suspected leukopenia. Rev Rhum Mal Osteoartic 52:145–150PubMed
19.
Zurück zum Zitat O’Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M, Kanis JA (1990) Treatment of Paget’s disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 5:483–491CrossRefPubMed O’Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M, Kanis JA (1990) Treatment of Paget’s disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 5:483–491CrossRefPubMed
20.
Zurück zum Zitat Arden-Cordone M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K (1997) Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of bone. Calcif Tissue Int 60:415–418CrossRefPubMed Arden-Cordone M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K (1997) Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of bone. Calcif Tissue Int 60:415–418CrossRefPubMed
Metadaten
Titel
Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report
verfasst von
A. Karahasanovic
A.-L. Thorsteinsson
N. H. Bjarnason
P. Eiken
Publikationsdatum
14.04.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 8/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3559-x

Weitere Artikel der Ausgabe 8/2016

Osteoporosis International 8/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.